Theriva Biologics FY EPS $(1.14) Beats $(1.28) Estimate; As Of December 31, 2023, Theriva Biologics Reports $23.2M In Cash, Which Is Expected To Provide Runway Into The First Quarter Of 2025
Theriva Biologics FY EPS $(1.14) Beats $(1.28) Estimate; As Of December 31, 2023, Theriva Biologics Reports $23.2M In Cash, Which Is Expected To Provide Runway Into The First Quarter Of 2025
Theriva Biologics財年每股收益美元（1.14美元）超過預期（1.28美元）；截至2023年12月31日，Theriva Biologics公佈了2320萬美元的現金，預計將爲2025年第一季度提供資金
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.28) by 10.94 percent. This is a 12.98 percent increase over losses of $(1.31) per share from the same period last year.
Theriva Biologics（美國證券交易所股票代碼：TOVX）公佈的季度虧損爲每股1.14美元，比分析師共識估計的美元（1.28美元）高出10.94％。與去年同期每股虧損1.31美元（1.31）相比，增長了12.98％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。